NCT03010527

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 217 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

Conditions

• Chronic Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Bimekizumab	Subjects will receive bimekizumab injections every four weeks (Q4W)
OTHER	Placebo	Subjects will receive Placebo injections every four weeks (Q4W)

Timeline

• Start date: 2016-12-14
• Primary completion: 2018-09-25
• Completion: 2018-09-25
• First posted: 2017-01-05
• Last updated: 2022-10-18
• Results posted: 2021-10-25

Locations

36 sites across 6 countries: United States, Canada, Czechia, Hungary, Japan, Poland

Regulatory

• FDA-regulated drug study